-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Collaborates with Nference for Cardiometabolic Research
Share
Listen to the news
05:57 AM EST, 11/18/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) partnered with artificial intelligence-focused healthcare research company Nference to advance research in cardiometabolic diseases, including obesity, diabetes and cardiovascular disease. The Danish drugmaker will contribute its clinical trial data, which will be analyzed using Nference's AI platform, according to a Wednesday release. The partners plan to identify new research opportunities that could lead to the development of future treatments. The deal also includes a framework to explore potential new health-focused ventures for cardiometabolic health and healthy aging.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending